115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1

Bioprocess development is transforming the biotech industry, driving innovations in life-changing therapies. Success hinges on simplifying complex mechanisms and adopting advanced technologies. By integrating high-throughput screening and artificial intelligence, we can streamline workflows, reduce trial-and-error, and speed up biologics development. Embracing cutting-edge tools empowers scientists to maximize biology's potential, delivering efficient and impactful biotech solutions.In this episode of The Smart Biotech Scientist Podcast, host David Brühlmann explores these transformative methodologies with Jeremy Agresti, CTO and founder of Triplebar.Jeremy highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI. With tools that enhance predictability, scalability, and efficiency, Triplebar is set to transform biotechnology. By reimagining traditional methods, improving inputs, and leveraging modern technology, companies like Triplebar are driving a new era in bioprocessing, offering innovative solutions to complex biological challenges.Key Takeaways:Jeremy challenges the traditional view of scale-up issues, emphasizing that many problems can be solved at a smaller scale with better engineered strains and cell lines.By creating tiny bioreactors of droplets, Triplebar is able to perform high throughput screening, testing millions of mutations quickly and efficiently, and providing robust solutions for complex biological functions.The integration of massive data sets with AI allows for improved enzyme and protein design, unlocking the potential to innovate even when foundational understanding is limited.Ready to dive deeper? Join the journey of transforming bioprocess development with smart insights and pioneering spirit. Catch up with Jeremy’s full story via the latest episode of the Smart Biotech Scientist podcast.Connect with Jeremy Agresti:LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/Triplebar: www.triplebar.comNext Steps:Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.comAre soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessmentSupport the show